UK Accelerates Review Times for Postmarket, Certain Phase 3 Trial Applications

Sponsors of postmarket trials and certain phase 3 trials can now expect the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to process their trial applications within two weeks rather than the statutory 30 days, as long as they meet certain criteria.
Source: Drug Industry Daily